Zynerba Press Releases

21 Nov 17 Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)

14 Nov 17 Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights

7 Nov 17 Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences

28 Sep 17 Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome

6 Sep 17 Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences

14 Aug 17 Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis

7 Aug 17 Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures

1 Aug 17 Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights

28 Jul 17 Zynerba Pharmaceuticals Mourns Passing of Director Cynthia A. Rask

26 Jun 17 Zynerba Pharmaceuticals Added to the Russell 3000® Index